前のページに戻るこの文献は全文を取り寄せることができます

JDreamⅢ複写サービスから文献全文の複写（冊子体のコピー）をお申込みできます。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。

既に、G-Searchデータベースサービスまたは、JDreamⅢのIDをお持ちの方

JDreamⅢ複写サービス
文献複写のお申込み

JDreamⅢ複写サービスのご利用が初めての方

学術文献の全文複写をお取寄せ
JDreamⅢ複写サービスのご案内

取り寄せる文献のタイトルと詳細

文献

J-GLOBAL ID：202202221623444854 整理番号：22A1151820

高リスク新たに診断された多発性骨髄腫に対する自己幹細胞移植後のレナリドマイド維持後の抗CD19および抗BCMA CAR T細胞療法【JST・京大機械翻訳】

Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma

著者 (25件)：

Shi Xiaolan

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Yan Lingzhi

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Shang Jingjing

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Kang Liqing

(Shanghai Unicar-Therapy Bio-medicine Technology Co. Ltd., Shanghai, China)

Yan Zhi

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Jin Song

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Zhu Mingqing

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Chang Huirong

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Gong Feiran

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Zhou Jiazi

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Chen Guanghua

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Pan Jinlan

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Liu Dandan

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Zhu Xiaming

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Tang Fang

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Liu Minghong

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Liu Wei

(Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Yao Feirong

(Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Yu Lei

(Shanghai Unicar-Therapy Bio-medicine Technology Co. Ltd., Shanghai, China)

Wu Depei

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Wu Depei

(Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

Wu Depei

(State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China)

Fu Chengcheng

(National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China)

Fu Chengcheng

(Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

Fu Chengcheng

(State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China)

資料名：

American Journal of Hematology (American Journal of Hematology)

巻： 97 号： 5 ページ： 537-547 発行年： 2022年
JST資料番号： E0721B ISSN： 0361-8609 資料種別：逐次刊行物 (A)
記事区分：原著論文発行国：アメリカ合衆国 (USA) 言語：英語 (EN)

JDreamⅢ複写サービスとは

JDreamⅢ複写サービスは、学術文献の全文を複写（コピー）して取り寄せできる有料サービスです。インターネットに公開されていない文献や、図書館に収録されていない文献の全文を、オンラインで取り寄せることができます。J-GLOBALの整理番号にも対応しているので、申し込みも簡単にできます。全文の複写（コピー）は郵送またはFAXでお送りします

※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。

TOP

BOTTOM